WO2026133251 - COMBINATIONS OF ANTISENSE AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2026/133251
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063182
International Filing Date
18.12.2025
Title **
[English]
COMBINATIONS OF ANTISENSE AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
[French]
COMBINAISONS D'AGENTS ANTISENS, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION
Applicants **
NOVARTIS AG
Inventors
HAEMMIG, Stefan
HAGEN, Caitlin Jeanette
HUNZIKER, Juerg
KIRSTEIN, Kathleen Finola
TAN, Ge
TRAUGER, John Wesley
WEILER, Jan
Priority Data
63/737,020
20.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9653 | |
| EPO | Filing, Examination, Granting | 64592 | |
| Japan | Filing, Examination, Granting | 3895 | |
| South Korea | Filing, Examination, Granting | 5488 | |
| USA | Filing, Examination, Granting | 21940 |
Total:
105,568
Contact Us
Abstract[English]
Disclosed are, inter alia, combinations comprising a first antisense (e.g., first double stranded RNAi (dsRNAi)) agent for inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, and a second antisense agent (e.g., second dsRNAi agent) for inhibiting expression of angiotensinogen (AGT); pharmaceutical compositions including the same, and methods of treatment using the same.[French]
L'invention concerne, entre autres, des combinaisons comprenant un premier agent antisens (par exemple, un premier agent ARNi double brin (ARNidb)) pour inhiber l'expression de la proprotéine convertase subtilisine kexine 9 (PCSK9), par exemple, PCSK9 humaine, et un second agent antisens (par exemple, un second agent ARNidb) pour inhiber l'expression de l'angiotensinogène (AGT) ; des compositions pharmaceutiques les comprenant, et des méthodes de traitement les utilisant.